SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

*TEL AVIV —* SciSparc Ltd. on July 18, 2025, received a written notice from
The Nasdaq Stock Market LLC indicating the Company has regained compliance
with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares
to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing
bid price of the Company’s ordinary shares was at $1.00 per share or
greater for 10 consecutive business days. Accordingly, the Company has
regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq
considers the prior bid price deficiency matter now closed.
About SciSparc Ltd.

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and scientists.
SciSparc’s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer’s disease and
agitation; and SCI-210 for the treatment of autism and status epilepticus.
The Company also owns a controlling interest in a subsidiary whose business
focuses on the sale of hemp seeds’ oil-based products on
the Amazon.com Marketplace.